Black Diamond Therapeutics (BDTX) Competitors $1.67 +0.08 (+5.03%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.67 0.00 (-0.06%) As of 03/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BDTX vs. ARCT, RVNC, ABVX, HUMA, AURA, RAPP, RNAC, TSHA, ATXS, and HRTXShould you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Arcturus Therapeutics (ARCT), Revance Therapeutics (RVNC), ABIVAX Société Anonyme (ABVX), Humacyte (HUMA), Aura Biosciences (AURA), Rapport Therapeutics (RAPP), Cartesian Therapeutics (RNAC), Taysha Gene Therapies (TSHA), Astria Therapeutics (ATXS), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry. Black Diamond Therapeutics vs. Arcturus Therapeutics Revance Therapeutics ABIVAX Société Anonyme Humacyte Aura Biosciences Rapport Therapeutics Cartesian Therapeutics Taysha Gene Therapies Astria Therapeutics Heron Therapeutics Black Diamond Therapeutics (NASDAQ:BDTX) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and earnings. Which has preferable earnings and valuation, BDTX or ARCT? Arcturus Therapeutics has higher revenue and earnings than Black Diamond Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlack Diamond TherapeuticsN/AN/A-$82.44M-$1.27-1.31Arcturus Therapeutics$138.39M2.35-$29.73M-$3.01-3.99 Do institutionals and insiders believe in BDTX or ARCT? 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 8.9% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 15.3% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer BDTX or ARCT? Arcturus Therapeutics received 391 more outperform votes than Black Diamond Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Black Diamond Therapeutics an outperform vote while only 66.27% of users gave Arcturus Therapeutics an outperform vote. CompanyUnderperformOutperformBlack Diamond TherapeuticsOutperform Votes5571.43% Underperform Votes2228.57% Arcturus TherapeuticsOutperform Votes44666.27% Underperform Votes22733.73% Is BDTX or ARCT more profitable? Black Diamond Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -36.39%. Arcturus Therapeutics' return on equity of -22.39% beat Black Diamond Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Black Diamond TherapeuticsN/A -68.08% -49.65% Arcturus Therapeutics -36.39%-22.39%-14.81% Does the media prefer BDTX or ARCT? In the previous week, Black Diamond Therapeutics had 10 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 12 mentions for Black Diamond Therapeutics and 2 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.71 beat Black Diamond Therapeutics' score of 0.90 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility and risk, BDTX or ARCT? Black Diamond Therapeutics has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the S&P 500. Do analysts prefer BDTX or ARCT? Black Diamond Therapeutics currently has a consensus price target of $14.60, indicating a potential upside of 774.25%. Arcturus Therapeutics has a consensus price target of $59.20, indicating a potential upside of 393.33%. Given Black Diamond Therapeutics' higher probable upside, equities research analysts clearly believe Black Diamond Therapeutics is more favorable than Arcturus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 SummaryArcturus Therapeutics beats Black Diamond Therapeutics on 11 of the 18 factors compared between the two stocks. Remove Ads Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDTX vs. The Competition Export to ExcelMetricBlack Diamond TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$94.63M$3.04B$5.65B$8.06BDividend YieldN/A1.54%4.57%4.01%P/E Ratio-1.2629.2923.1619.03Price / SalesN/A436.17386.8193.17Price / CashN/A168.6838.1634.64Price / Book0.743.956.914.33Net Income-$82.44M-$71.95M$3.20B$247.06M7 Day Performance-6.18%-3.76%-2.30%-0.37%1 Month Performance-16.92%-10.33%2.86%-3.85%1 Year Performance-67.06%-27.15%10.51%1.27% Black Diamond Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDTXBlack Diamond Therapeutics3.236 of 5 stars$1.67+5.0%$14.60+774.3%-65.9%$94.63MN/A-1.2690High Trading VolumeARCTArcturus Therapeutics3.1077 of 5 stars$14.16+0.6%$59.20+318.1%-63.5%$384.02M$138.39M-6.38180Positive NewsRVNCRevance Therapeutics2.0174 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Analyst ForecastABVXABIVAX Société Anonyme2.0608 of 5 stars$6.00+1.0%$38.67+544.4%-53.9%$380.30MN/A0.0061Analyst RevisionNews CoverageGap DownHigh Trading VolumeHUMAHumacyte2.165 of 5 stars$3.01-1.0%$13.71+355.6%-35.2%$378.84M$1.57M-2.25150Upcoming EarningsAnalyst ForecastNews CoverageAURAAura Biosciences2.1763 of 5 stars$7.54+2.6%$23.00+205.0%-22.9%$376.63MN/A-4.3650Earnings ReportAnalyst RevisionNews CoverageHigh Trading VolumeRAPPRapport Therapeutics1.7424 of 5 stars$10.18-3.1%$35.00+243.8%N/A$371.53MN/A-0.74N/AShort Interest ↑RNACCartesian Therapeutics2.4042 of 5 stars$14.44-8.6%$42.14+191.8%-27.5%$366.99M$47.94M-0.2764Positive NewsTSHATaysha Gene Therapies2.761 of 5 stars$1.79+4.1%$6.63+270.1%-40.7%$366.95M$8.33M2.84180Positive NewsATXSAstria Therapeutics1.7843 of 5 stars$6.48+0.5%$26.67+311.5%-55.4%$365.69MN/A-3.1030Positive NewsHRTXHeron Therapeutics3.8848 of 5 stars$2.39+3.0%$5.67+137.1%-15.7%$364.07M$144.29M-13.28300Positive News Remove Ads Related Companies and Tools Related Companies ARCT Competitors RVNC Competitors ABVX Competitors HUMA Competitors AURA Competitors RAPP Competitors RNAC Competitors TSHA Competitors ATXS Competitors HRTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDTX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BDTX Stock Free BDTX Stock Alerts